Cynomolgus / Rhesus PD-L1 / B7-H1 / CD274 Protein (His Tag)

CD274

100ug (NPP1076) Please inquiry

Catalog Number	P90251-C08H
Organism Species	Cynomolgus
Host	Human Cells
Synonyms	CD274
Molecular Weight	The recombinant cynomolgus/rhesus CD274 comprises 232 amino acids and has a calculated molecular mass of 26.7 KDa. The apparent molecular mass of it is approximately 37 KDa in SDS-PAGE.
predicted N	Phe 19
SDS-PAGE
Purity	> 95 % as determined by SDS-PAGE
Protein Construction	A DNA sequence encoding the cynomolgus/rhesus CD274 (F6VEW6) (Met1-Thr239) was expressed with a polyhistidine tag at the C-terminus. Cynomolgus and Rhesus CD274 sequences are identical.
Bio-activity	Measured by its binding ability in a functional ELISA. Immobilized Cynomolgus CD274-His at 10 μg/ml (100 μl/well) can bind Cynomolgus PDCD1-Fc (Cat：90311-C02H), The EC₅₀ of Cynomolgus PDCD1-Fc (Cat：90311-C02H) is 1.0-2.3μg/ml.
Research Area	Immunology \|Innate Immunity \|Monocytes/Macrophages \|Macrophage Markers
Formulation	Lyophilized from sterile PBS, pH 7.4. 1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background	Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.
Reference	Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7. Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8. Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94. Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58. Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.